Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide is highly effective for decreasing weight. Concomitant loss of muscle mass often accompanies weight loss and may have consequences on muscle function. METHODS: This is a secondary analysis from the SLIM LIVER (Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, ACTG A5371) study, a single-arm study of semaglutide in people with human immunodeficiency virus (HIV, PWH) with metabolic dysfunction-associated steatotic liver diseases (MASLD). Participants received subcutaneous semaglutide for 24 weeks (titrated to 1 mg/week by week 4). Psoas volume and fat fraction were assessed from liver magnetic resonance imaging, and physical function was assessed by 10-time chair rise test and 4 m gait speed. Mean change from baseline to week 24 was estimated with linear regression modeling. RESULTS: Fifty-one PWH were enrolled (muscle measures n = 46). The mean age was 50 years (standard deviation, 11), body mass index was 35.5 kg/m2 (5.6), 43% were women, 33% Black, and 39% Hispanic/Latino. Psoas muscle volume decreased by 9.3% (95% confidence interval [CI]: -13.4 to -5.2; P < .001) over 24 weeks, but psoas muscle fat did not significantly change (-0.42%; 95% CI: -1.00 to .17; P = .16). Chair rise and gait speed showed nonsignificant improvements of 1.27 seconds (95% CI: -2.7 to .10) and 0.05 m/sec (95% CI: -.01 to .10), respectively (both P > .07). The prevalence of slow gait speed (<1 m/sec) decreased from 63% to 46% (P = .029). CONCLUSIONS: In PWH receiving semaglutide for MASLD, despite decreased psoas muscle volume, there was no significant change in physical function, suggesting function was maintained despite significant loss of muscle. CLINICAL TRIALS REGISTRATION: NCT04216589.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The trial, which led to the approval of semaglutide for obesity treatment, revealed that up to 40% of total body weight loss could be attributed to lean body mass reduction, exceeding the approximate 25% commonly seen with standard caloric restriction [2].”
From Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions (2025) · cites this paper as [2]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International physical activity questionnaire: 12-country reliability and validity
CRAIG, C. L., MARSHALL, A. L., SJ??STR??M, M., BAUMAN, A. E., BOOTH, M. L., AINSWORTH, B. E., PRATT, M., EKELUND, U., YNGVE, A., SALLIS, J. F., et al. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000078924.61453.fb · Cited by 21,619
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Weight loss, exercise, or both and physical function in obese older adults
Villareal, D. T., Chode, S., Parimi, N., Sinacore, D. R., Hilton, T., Armamento-Villareal, R., Napoli, N., Qualls, C., & Shah, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008234 · Cited by 1,096
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Targher, G., Byrne, C. D., & Tilg, H. (2020) · Gut · doi:10.1136/gutjnl-2020-320622 · Cited by 827
Research works printed but not linked: 1
- Eckard, 2024, Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial, Lancet Diabetes Endocrinol, S2213–8587, 00150-5
Cited by
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Pharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
“In NCT04216589, conducted in patients with NAFLD and HIV, semaglutide led to reductions in steatosis ( − 4.2%), HbA1c, weight ( − 7.8 kg), BMI ( − 2.8 units), and waist circumference ( − 6.7 cm) [75].”
InfluentialKunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 44
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101681 · Cited by 30
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102665 · Cited by 21
Artificial Intelligence in Clinical Nutrition: Bridging Data Analytics and Nutritional Care
Varayil, J. E., Bielinski, S. J., Mundi, M. S., Bonnes, S. L. R., Salonen, B. R., & Hurt, R. T. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00680-x · Cited by 16
(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
von Haehling, S., Sato, R., Langer, H., Khan, M. S., Coats, A. J. S., Evans, W., Heymsfield, S., & Anker, S. D. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.70147 · Cited by 10
Muscle health in the modern era of incretin‐based therapies
Girolamo, G. D., Sangineto, M., Gioia, G. D., Bianco, R., Ciarnelli, M., & Serviddio, G. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70155 · Cited by 16
Impact of Incretin-Based Therapy on Skeletal Muscle Health
Koceva, A., Janež, A., & Jensterle, M. (2025) · Medicina · doi:10.3390/medicina61091691 · Cited by 16
Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments
Pryke, L. A., Koethe, J. R., & Bailin, S. S. (2026) · Current HIV/AIDS Reports · doi:10.1007/s11904-026-00776-1 · Cited by 13
Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study
Corley, M. J., Pang, A. P. S., Kitch, D. W., Kantor, A., Sattler, F. R., Belaunzarán-Zamudio, P. F., Brown, T. T., LANDAY, A. L., Lake, J. E., & Erlandson, K. M. (2026) · npj Aging · doi:10.1038/s41514-026-00383-9 · Cited by 13
Self-citationLiver disease in people living with HIV infection: a changing landscape
Lee, F., & Bansal, M. B. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01149-6 · Cited by 8
Nalbandian, M., Lone, J. B., Moal, E. L., Kim, I., Jeuris, K., Li, Y. K., Kraft, P. E., Zhao, M., Koleckar, K., Zhang, Z., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2606533123 · Cited by 10
Iorra, F. D. Q., Jayakar, T., Yee, M. S., Thursz, M. R., Schaan, B. D., & Manousou, P. (2026) · Liver International · doi:10.1111/liv.70643 · Cited by 8
GLP-1-derived therapies and risk of sarcopenia: myth or reality?
Scheen, A. J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2640980 · Cited by 5
Genton, L., Sanz, M. L., Arvanitakis, M., Ballesteros-Pomar, M. D., Bally, L., Barazzoni, R., Betry, C., Burgos, R., Cuerda, C., Hadefi, A., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.106550 · Cited by 4
Kulik, G. L., Oliveira, V. H. F., Wilson, M. P., Khuu, V., Jankowski, C. M., Dillon, S. M., Cook, P., MaWhinney, S., Ghosh, D., Webel, A. R., et al. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag113 · Cited by 3
Self-citationSamajdar, S. S., & Joshi, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70242 · Cited by 1
Sanchis‐Gomar, F., Neeland, I. J., Ruiz‐Lozano, P., Alnahar, O., & Rodríguez, F. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02334-4 · Cited by 1
Nakano, Y., Morita, S., Nishi, N., Kita, M., Shimo, N., Takeshima, K., Furukawa, Y., & Matsuoka, T. (2026) · Diabetology International · doi:10.1007/s13340-026-00882-w · Cited by 1
Sancho-Haro, E. S., Muñoz-López, M., Baz-Valle, E., Villanueva-Tobaldo, C. V., Tornero-Aguilera, J. F., López-Gil, J. F., López‐Moreno, M., Martín-Rodríguez, A., & Clemente‐Suárez, V. J. (2026) · Pharmaceuticals · doi:10.3390/ph19060897 · Cited by 2
Nalbandian, M., Lone, J., Moal, E. L., Kim, I., Li, Y., Kraft, P., Zhao, M., Kolacar, K., Zhang, Z., Svensson, K. J., et al. (2026) · bioRxiv · doi:10.64898/2026.02.26.708119 · Cited by 1
New Updates in Adipocytes and Adipose Tissue: 2nd Edition
Kristóf, E., & Csősz, É. (2026) · Life · doi:10.3390/life16040619 · Cited by 1
Psomas, C. K., & Loes, S. K. (2024) · Journal of Virus Eradication · doi:10.1016/j.jve.2024.100372
Alagaratnam, J., Levi, L. I., van Bremen, K., Mastrángelo, A., & Ambrosioni, J. (2024) · CMI Communications · doi:10.1016/j.cmicom.2024.100006
CROI 2024 BHIVA working group summary
Barber, T., Clarke, A. E., Fox, A., Mackie, N., Sabin, C. A., & Waters, L. J. (2024) · HIV Medicine · doi:10.1111/hiv.13705
Patoulias, D., Karakasis, P., Ruža, I., El‐Tanani, M., & Rizzo, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2435426 · Cited by 1
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rhouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E. D. F., et al. (2025) · medRxiv · doi:10.1101/2025.07.28.25332295
Myosteatosis in HIV: the adipose tissue connection
Masenga, S. K., & Capeau, J. (2025) · AIDS · doi:10.1097/qad.0000000000004285
Tomasiewicz, A., Zabierowski, J., Pachana, M., Kukuła, P., Piersiak, M., Sawczuk, H., Marschollek, J., & Ziomek, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.4067
Sarcopenia in Asian Patients in the Era of SGLT2i and GLP-1RA: A Clinical Concern?
Alam, A., Salman, M., Mahfooz, S., & Mahmood, S. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_30_26
Haidar, L., & Delaney, J. A. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001059 · Cited by 1
Ahmed, A. K. K., Rodini, S., Alrubyea, F., & Akl, M. M. (2026) · Problems of Endocrinology · doi:10.14341/probl13660
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity
Mollero, E. L. M., Dozzani, I., Biamonte, E., Bendotti, G., Marzullo, P., Aimaretti, G., & Gallo, M. (2026) · Nutrients · doi:10.3390/nu18162654 · Cited by 2
Jagasia, K., Pfeiffer, A. M., & Vitale, K. (2026) · Journal of Aging Research and Lifestyle · doi:10.1016/j.jarlif.2026.100083 · Cited by 2
Reframing obesity in aging people with HIV: sarcopenic obesity, muscle quality, and frailty
Oliveira, V. H. F., Brown, T. T., & Erlandson, K. M. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001067 · Cited by 1
Self-citationSebastiani, G., Lee, T.-H. “., Cordie, A., Cinque, F., Lake, J. E., Lazarus, J. V., Rockstroh, J. K., & Guaraldi, G. (2026) · The Lancet HIV · doi:10.1016/s2352-3018(26)00172-4
Self-citationMokrzecki, S., Mamach, A., Bełc, E., Brzezińska, K., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Król, M., Straszewska, A., Woźniak, A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6230
Knapik, J., Fic, W., & Polak-Szczybyło, E. (2026) · Nutrients · doi:10.3390/nu18193247
Cuggy, C., & O’Broin, E. (2026) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojag163 · Cited by 1
Functional Implications of GLP-1RA Use Beyond Obesity in Aging Adults
Mascone, S. E., Prior, S. J., & Addison, O. R. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00467-0
Nutritional Impairment and Muscle Health in MASLD: The Potential Role of Eating Behaviors
Armașu, I., Ungureanu, M.-C., Gheorghe, L., Botnariu, G., Florescu, A.-F., Matei, A., Jari, I., Rusu, R. E., Cojocaru, E., Vasiliu, I., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15218306
Metadata
- Authors
- Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., Avihingsanon, A., Sattler, F. R., & Erlandson, K. M.
- Affiliations
- University of Colorado Anschutz (US)
- The University of Texas Health Science Center at Houston (US)
- Harvard University (US)
- Texas A&M University (US)
- National Institute of Allergy and Infectious Diseases (Contractor) , Rockville, Maryland ,
- Johns Hopkins University (US)
- The University of Texas Medical Branch at Galveston (US)
- Thai Red Cross Society (TH)
- University of Southern California (US)
- Corresponding author
- Ditzenberger, Grace L
- Erlandson, Kristine M
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-07-24
- Volume
- 80
- Issue
- 2
- Pages
- 389-396
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC11848261
- OpenAlex
- W4400967991
- Cited by
- 44
- References
- 40
- Citations by year
- 2026: 24 · 2025: 15 · 2024: 5
- FWCI
- 23.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIAID (UM1 AI068634, UM1 AI068636, UM1 AI106701)
- NIH
- McGovern School of Medicine at UTHealth (T32 AI150547, K24 AI120834)
- National Institute on Aging (K24 AG082527)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- semaglutide, HIV, non-alcoholic fatty liver disease, muscle mass loss, muscle fat fraction, physical function, walking speed, chair stand test, weight loss, GLP-1 receptor agonists
- MeSH terms
- Semaglutide, Adult, Glucagon-Like Peptides, Fatty Liver, Female, Humans, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Weight Loss, HIV Infections, Psoas Muscles, Muscle, Skeletal, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.